Update on Nyrada's Brain Injury program

Nyrada Inc (ASX:NYR) has successfully completed a dog toxicology study for its lead candidate, NYR-BI03, under Good Laboratory Practice (GLP) conditions. The study focused on assessing NYR-BI03's safety and tolerability profile, marking a significant milestone in the company's Brain Injury program. Nyrada remains on track to commence the first in-human Phase I clinical trial for NYR-BI03 in late CY2024.

Executive Commentary on Dog Toxicology Study

This successful completion of the dog toxicology study for NYR-BI03 under GLP conditions is a crucial step forward in our Brain Injury program. The study provides valuable data supporting the safety and tolerability of our lead candidate, reinforcing our confidence in its potential for further development. We are pleased with the results and remain focused on progressing towards the first in-human Phase I clinical trial for NYR-BI03 in late CY2024.

Summary of Nyrada's Brain Injury Program Update

Nyrada Inc (ASX:NYR) has achieved a significant milestone with the successful completion of the dog toxicology study for its lead Brain Injury drug candidate, NYR-BI03. The study, conducted under GLP conditions, demonstrated the safety and tolerability of NYR-BI03, positioning the company to advance towards the first in-human Phase I clinical trial. NYR-BI03, a first-in-class neuroprotection treatment for stroke and traumatic brain injury, has shown promising preclinical results, and Nyrada is on track to submit a Human Research Ethics Application with the expectation of commencing the Phase I trial in late 2QFY2025. The completion of this study marks significant progress in Nyrada's efforts to address unmet clinical needs in the treatment of brain injuries, and the company remains committed to advancing its innovative therapies for the benefit of patients.